The phrase "active tender" is not a standard expression in written English and may cause confusion without context.
It could potentially be used in contexts related to finance or procurement, where "active" describes a current or ongoing tender process.
Example: "The company is currently reviewing proposals for the active tender for the new construction project."
Alternatives: "current tender" or "ongoing tender".
Originally IBS patients without FMS showed somatic hyposensitivity at active somatic tender points, non-tender control sites and the T-12 dermatome [ 10].
*p < 0.05 The influence of arthritis-related factors assessed at both baseline and 10 years on BMDa are shown in Table 2. Disease activity expressed as active (swollen, tender or both) counts assessed either at baseline or at the 10th anniversary visit showed no association with BMDa.
Results through week 24 of this multicentre, randomised, double-blind, placebo-controlled study of active RA (≥4 tender, ≥4 swollen joints) were previously reported.
Patients enrolled into this multicenter, randomized, double-blind, placebo-controlled study of active RA (≥4 tender, ≥4 swollen joints) received placebo (Group 1) or golimumab 50 mg (Group 2) or 100 mg (Group 3) injections every 4 weeks.
Eligible patients were ≥18 years old, with RA for ≥6 months diagnosed by the American College of Rheumatology (ACR) 1987 Revised Criteria, with active disease (≥6 tender joints and ≥6 swollen joints; erythrocyte sedimentation rate >28 mm/h (measured in the local laboratory); and/or C-reactive protein >7 mg/L).
The lower limb muscle compartments were not firm or tender, and active extension of the knee and ankle did not exacerbate pain.
Patients had active disease by ≥5 tender and ≥4 swollen joints (TJC; SJC [28-joint count]) and either C-reactive protein (CRP) ≥10 mg/l or ESR (Westergren method) ≥28 mm/h at screening.
Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to subcutaneous injections of placebo, golimumab 50 mg or 100 mg every 4 weeks (q4wks) through week 20.
Two specific test points were chosen: the non-dominant elbow (the midpoint of the elbow crease in the cubital fossa) as the non-tender point (control site), and the right trapezius (midpoint of the trapezius muscle) as the tender point (active site).
Adult patients (aged ≥18 years; ≥20 years at Japanese sites) with a diagnosis of RA 8 for ≥4 months, active disease (≥6 swollen/≥6 tender joints), a serum C-reactive protein (CRP) level ≥10.0 mg/L, and a positive anti-cyclic citrullinated peptide antibody or rheumatoid factor status were enrolled.
